Ovoca Bio Plc Logo

Ovoca Bio Plc

OVXA | IR

Overview

Corporate Details

ISIN(s):
IE0006649010 (+1 more)
LEI:
213800ST2AK5XQ1O5207
Country:
Ireland
Address:
17 PEMBROKE STREET UPPER, D02 AT22 DUBLIN
Sector:
Professional, scientific and technical activities
Industry:
Research and experimental development on natural sciences and engineering

Description

Ovoca Bio Plc is a clinical-stage biopharmaceutical company with a primary focus on women's health. The company is dedicated to developing novel treatments for female sexual dysfunction. Its lead product candidate, Orenetide (also known as BP-101), is a synthetic peptide designed for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women and has progressed to late-stage clinical development. Recent corporate activity indicates a potential strategic shift, with the company exploring a reverse takeover involving mining assets.

Social Media

Stop Scraping. Start Analyzing.

You're viewing a fraction of the data available for Ovoca Bio Plc. Get complete, real-time, and AI-ready data via the API the pros use.

Get Instant API & Bulk Data Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-06-05 08:00
Delisting Announcement
Delisting from Euronext Growth Exchange
English 9.0 KB
2025-03-03 15:00
Board/Management Information
Management Changes
English 8.0 KB
2024-12-18 19:00
Post-Annual General Meeting Information
Result of AGM
English 7.1 KB
2024-11-18 08:00
Pre-Annual General Meeting Information
Notice of AGM
English 7.0 KB
2024-10-11 18:30
Major Shareholding Notification
Holding(s) in Company
English 6.8 KB
2024-10-09 18:45
Transaction in Own Shares
Sale of Treasury Shares
English 6.0 KB
2024-09-25 08:00
Report Publication Announcement
Half-year Report
English 7.6 KB
2024-09-02 15:30
Related Party Transaction
Consultancy Agreement
English 8.7 KB
2024-07-15 08:00
Director's Dealing
Director/PDMR Shareholding
English 27.4 KB
2024-07-15 08:00
Board/Management Information
Directorate Change
English 8.8 KB
2024-06-28 08:00
Report Publication Announcement
Annual Financial Report
English 14.5 KB
2024-06-20 00:00
Annual Report
English 1.2 MB
2024-01-23 08:00
Major Shareholding Notification
Holding(s) in Company
English 7.9 KB
2023-12-01 13:00
Post-Annual General Meeting Information
Result of AGM
English 7.8 KB
2023-11-07 10:15
Pre-Annual General Meeting Information
Notice of AGM
English 8.3 KB

Automate Your Workflow. Get a real-time feed of all Ovoca Bio Plc filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Ovoca Bio Plc via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
1NKEMIA Logo
Offers contract R&D, develops tech platforms, and invests in life sciences ventures.
Spain IKM
2cureX AB Logo
Tests cancer drugs on patient-derived micro-tumors for personalized oncology treatments.
Sweden 2CUREX
4SC AG Logo
Developing epigenetic small-molecule drugs for cancers with high unmet medical needs.
Germany VSC
Abera Bioscience AB Logo
Develops next-gen mucosal vaccines using an OMV platform for major infectious diseases.
Sweden ABERA
ABIVAX Logo
Developing oral drugs for chronic inflammatory diseases like ulcerative colitis and Crohn's disease.
France ABVX
Abliva Logo
A clinical-stage biotech developing medicines for rare primary mitochondrial diseases.
Sweden ABLI
Achiko AG Logo
A liquidated health tech firm that developed aptamer diagnostics and a COVID-19 passport app.
Switzerland ACHI
Acticor Biotech Logo
Biopharma developing first-in-class drugs for acute stroke and other thrombotic diseases.
France ALACT
Active Biotech Logo
Develops immunotherapies for cancer and inflammatory diseases with significant unmet needs.
Sweden ACTI
Addex Therapeutics Ltd Logo
Develops oral small molecule drugs, allosteric modulators, for neurological disorders.
Switzerland ADXN